ArticleBMJ open2018

Quality of evidence considered by Health Canada in granting full market authorisation to new drugs with a conditional approval: a retrospective cohort study.

Joel LexchinPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.